Growth Hormone Secretagogues
CJC-1295, ipamorelin, sermorelin, tesamorelin, MK-677 — what's approved, what's compounded, what's hype.
What's covered
Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.
By the end of this module you will be able to
- L01Distinguish FDA-approved secretagogues (tesamorelin) from compounded peptides.
- L02Counsel a patient on the IGF-1 / glucose / sleep apnea risk triad.
What you should walk away believing
Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.
What this means for you
These peptides ask your pituitary to make more growth hormone. Only one (tesamorelin) is approved for a specific HIV-related condition. Most are sold by anti-aging clinics with very thin evidence and real metabolic risks.
CJC-1295/ipamorelin stacks dominate the compounded market. Patients often present with elevated IGF-1, new glucose intolerance, fluid retention, or worsened OSA. Ask about peptide use in any patient with new acromegaloid symptoms.
Mechanistic case for cycling GH/IGF-1 elevation as either anti- or pro-aging is unresolved; mTOR/IGF-1 pathways favor longevity at lower tone in model organisms — at odds with the marketing.
What the data say
Test yourself
Lock it in — review what's due
Key terms & abbreviations
- GHSGrowth hormone secretagogue
- Any molecule that promotes endogenous GH release, typically via GHRHR or GHSR (ghrelin) agonism.
Sources cited in this module
- [1]World Anti-Doping Code Prohibited List 2025WADA · 2025Regulatory · T1
- [2]Category 2 list — bulk drug substances under 503A (includes ipamorelin, CJC-1295, BPC-157)FDA Pharmacy Compounding Advisory Committee · 2023Regulatory · T1
- [3]Evaluation and Treatment of Adult Growth Hormone Deficiency: Endocrine Society GuidelineMolitch ME. et al. · JCEM · 2011Guideline · T1
- [4]Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adultsTeichman SL. et al. · JCEM · 2006RCT · T2